- Home
- / Fulcrum Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Fulcrum Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.2
2024-10-29
Market Capitalization
$202.2 M
2024-10-29
Revenue
$80 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.8M | 19.2M | 6.3M | 2.8M | 80.0M | ||||
| General and administrative expense | 4.5M | 8.3M | 13.1M | 21.4M | 30.5M | 41.7M | 41.7M | 36.4M | 28.7M |
| Operating expense total | 23.0M | 33.5M | 84.2M | 80.4M | 100.2M | 118.5M | 113.5M | 99.8M | 84.8M |
| EBIT | (23.0M) | (33.5M) | (84.2M) | (71.6M) | (81.1M) | (112.6M) | (110.7M) | (21.9M) | (84.8M) |
| EBIT margin, % | -811.6% | -423.0% | -1774.9% | -3945.2% | -27.4% | ||||
| Interest income | 1.0K | 518.0K | 29.0K | ||||||
| Interest expense | 1.5M | 792.0K | 207.0K | 2.7M | 13.3M | 12.2M | 9.9M | ||
| Net Income | (23.0M) | (32.6M) | (82.7M) | (70.8M) | (80.8M) | (109.9M) | (97.3M) | (9.7M) | (74.9M) |
| EPS | (2.3) | (2.4) | (1.6) | (0.2) | (1.2) |